If everything goes well, the company expects to seek approval for Linzagolix in Europe by year-end 2020 and in the U.S. by the first quarter of 2021. SHARE THIS POST ObsEva NewsMORE your MARKET VIEW …
More Stock To Watch: ObsEva’s PRIMROSE 2 Trial Meets Goals Videos